



Call to waive COVID vaccine patents

The U.S. has joined India and South Africa in calling for a waiver on COVID vaccine patents, to allow any manufacturer in the world to produce their own copies without fear of infringing intellectual property rights



Unlike other major vaccine producers, U.S. reserves most for domestic use

DOSES PER 100 PEOPLE May 7
No data 0 1 5 10 20 40 100



VACCINE PRODUCTION

Doses as of March 3

China Sinovac, Sinopharm, CanSino, Astra Zeneca **141.6 million**

U.S. Pfizer/BioNTech, Moderna **103m**

Germany/Belgium/Netherlands **81m** Pfizer, AZ

India **42.4m** AZ, Bharat

UK **12.2m** AZ

Russia **10.5m** Sputnik V

Switzerland **5.5m** Moderna

South Korea **1.6m** AZ

Brazil **0.2m** Sinopharm

South Africa **0.16m** J&J

Germany claims manufacturing capacity and standards are limiting production, not patents. Pfizer CEO **Albert Bourla** says theirs are the only facilities that can manufacture mRNA vaccines



Sources: Our World in Data, Airfinity

© GRAPHIC NEWS